Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1066 in Healthy Volunteers and Psoriasis/Atopic Dermatitis Patients
NCT03542994Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP1066 in psoriasis and atopic dermatitis (AD) (9 cohorts), sponsored by Evelo Biosciences. Primary endpoints: Safety and tolerability measured through Adverse Events, Safety and tolerability measured through lab measurements and 3 more. Started Apr 2019; status: completed.
02
Drugs
EDP1066
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03542994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542994.